References
Gibeaut J (1996) Rank speculation. Some big-name law schools fare poorly in new, controversial by a former Michigan justice. ABA J 42–43
Gladwell M (2011) The order of things. What college rankings really tell us. The New Yorker, February 14 & 21, 2011, 68–75
McColl E, Jacoby A, Thomas L, Soutter J, Bamford C, Steen N, Thomas R, Harvey E, Garratt A, Bond J (2001) Design and use of questionnaires: a review of best practices applicable to surveys of health service staff and patients. Health Technol Assess 5–31
Hing CB, Smith TO, Hooper L, Song F, Donell ST (2011) A review of how to conduct a surgical survey using a questionnaire. Knee 18(4):209–213
Engstrom RE Jr, Holland GN, Nussenblatt RB, Jabs DA (1991) Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol 111(5):601–610
Cunningham ET Jr, Hubbard LD, Danis RP, Holland GN (2011) Proportionate topographic areas of retinal zones 1, 2, and 3 for use in describing infectious retinitis. Arch Ophthalmol 129(11):1507–1508
Holland GN, Lewis KG (2002) An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol 134(6):102–114
Wakefiled D, Cunningham ET Jr, Pavesio C, Garweg JG, Zierhut M (2011) Controversies in ocular toxoplasmosis. Ocul Immunol Inflamm 19(1):2–9
Lum F, Jones JL, Holland GN, Liesegang TJ (2005) Survey of ophthalmologists about ocular toxoplasmosis. Am J Ophthalmol 140(4):724–727
Nguyen QD, Hatef E, Kayen B, Macahilig CP, Ibrahim M, Wang J, Shaikh O, Bodaghi B (2011) A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology 118(1):184–190
Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492–513
Esterberg E, Acharya NR (2011) Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect (in press)
Gangaputra S, Newcomb CW, Liesegang TL, Kaçmaz RO, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, Kempen JH (2009) Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases. Ophthalmology 116(11):2188-98.e1
Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kaçmaz RO, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Foster CS, Jabs DA, Kempen JH (2010) Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 149(3):423–432.e1-2
Cunningham ET Jr, Goldstein DA, Zierhut M. Uveitis treatment trials – A cross trial perspectives. Ocul Immunol Inflamm 2012; 20(2):63–67
Goldstein DA, Fontanilla FA, Kaul S, Sahin O, Tessler HH (2002) Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 109:370–377
Birnbaum AD, Oh F, Sahin O, Little DM, Tessler HH, Goldstein DA (2010) Chlorambucil and malignancy. Ophthalmology 117(7):1466–1466.e1
Zaghetto JM, Yamamoto MM, Souza MB, Silva FT, Hirata CE, Olivalves E, Yamamoto JH (2010) Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study. Arq Bras Oftalmol 73(1):40–46
Rosenbaum JT (2010) Future of biological therapy for uveitis. Curr Opin Ophthalmol 21(6):473–477
Hemmati HD, Dunn JP (2010) Biologic therapy for uveitis. Expert Rev Ophthalmol 5(2):225–239
Lee FF, Foster CS (2010) Pharmacotherapy of uveitis. Expert Opin Pharmacother 11(7):1135–1146
Heiligenhaus A, Thurau S, Hennig M, Grajewski RS, Wildner G (2011) Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol 248(11):1531–1551
Larson T, Nussenblatt RB, Sen HN (2011) Emerging drugs for uveitis. Expert Opin Emerg Drugs 16(2):309–322
Benitah NR, Sobrin L, Papaliodis GN (2011) The use of biologic agents in the treatment of ocular manifestations of Behcet's disease. Semin Ophthalmol 26(4–5):295–303
Deuter CM, Zierhut M, Möhle A, Vonthein R, Stöbiger N, Kötter I (2010) Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum 62(9):2796–2805
Galor A, Jabs DA, Leder HA, Kedhar SR, Dunn JP, Peters GB 3rd, Thorne JE (2008) Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 115(10):1826–1832
Kaçmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Levy-Clarke GA, Foster CS (2010) Cyclosporine for ocular inflammatory diseases. Ophthalmology 117(3):576–584
Smith JR, Jabs DA, Briceland DJ, Holland GN (2008) Education in the ophthalmic discipline of uveitis. Am J Ophthalmol 146(6):799–801
Vakil N (2011) Consensus guidelines: method or madness? Am J Gastroenterol 106(2)S:225–227
Holland GN (2003) Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease Am J Ophthalmol 136(6):973–988
Holland GN (2004) Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management Am J Ophthalmol 137(1):1–17